Source: International Congress 2019 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Takaki (Tokyo, Japan), A. Aono (Tokyo, Japan), K. Chikamatsu (Tokyo, Japan), Y. Igarashi (Tokyo, Japan), Y. Shimomura (Tokyo, Japan), Y. Murase (Tokyo, Japan), H. Yoshida (Osaka, Japan), . Tamura (Osaka, Japan), T. Nagai (Osaka, Japan), Y. Morishige (Tokyo, Japan), H. Yamada (Tokyo, Japan), S. Mitarai (Tokyo, Japan). Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan. 2137

Member's Comments

No comment yet.

Related content which might interest you: Resistance genotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Serbia Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Genetic diversity of M. tuberculosis isolates from patients with drug-resistant TB in Japan Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity Year: 2018 Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 Mycobacterium tuberculosis drug resistance surveillance in Belarus Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 Estimation of susceptibility hospital strains of Mycobacterium tuberculosis (Mtb) Beijing to disinfectants Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017 Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 High incidence of the Beijing strains among multi drug resistance isolates of Mycobacterium tuberculosis from extra pulmonary tuberculosis cases in northern India Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 MIC and gyrA/B genetic analyses of fluoroquinolones against mycobacterium tuberculosis isolated in Japan Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001 Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Emergence of drug resistance in mycobacterium tuberculosis isolates in Ibadan, Nigeria Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Treatment of drug-susceptible and drug-resistant tuberculosis Source: Eur Respir Monogr 2018; 82: 152-178 Year: 2018 Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020